Lund, Sweden — September 2, 2025 — Leads & Copy — Alligator Bioscience (Nasdaq Stockholm:ATORX) announced an evaluation and option agreement with an infectious disease company for its RUBY™ bispecific antibody format.
The agreement focuses on applying the RUBYTM platform to specific infectious diseases, featuring a two-year evaluation period. The counterparty holds an exclusive option to negotiate a license agreement based on evaluating certain antibodies in the RUBY™ format. Alligator will receive option fee installments totaling USD 75,000.
CEO Søren Bregenholt stated that this agreement exemplifies how Alligator’s innovation can foster products and generate non-dilutive financing, while the company remains focused on advancing mitazalimab into Phase 3 and securing a commercial partnership.
RUBY™ is Alligator’s proprietary format for creating bispecific antibodies designed to bind two targets at once and provide high stability and therapeutic potential. Orion Corporation has committed to two RUBY™-based antibodies.
Søren Bregenholt, CEO, soren.bregenholt@alligatorbioscience.com, +46 (0) 46 540 82 00
Source: Alligator Bioscience
